Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Copanlisib produces promising results in relapsed/refractory follicular lymphoma

George Follows • 14 Jun 2017
ICML 2017
Follicular Lymphoma Copanlisib

George Follows, MA, PhD, MRCP, FRCPath from Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK discusses the latest early-phase clinical trial data on copanlisib, presented at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. Indolent relapsed/refractory lymphoma patients receiving copanlisib as part of the trial tolerated the treatment well, with fewer of the adverse events typically linked to PI3K inhibitors. Dr Follows explains the promising data and the implications of these findings.

More from George Follows

3:58
Five-year follow up of the UK CLL Forum ibrutinib data
George Follows • 20 Sep 2019
1:21
Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
George Follows • 2 May 2018
1:11
PEP-C for treatment of relapsed/refractory lymphoma
George Follows • 2 May 2018
2:06
MURANO study: exciting times in CLL
George Follows • 9 Dec 2017

Related Videos

1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
0:55
Mosunetuzumab in untreated FL and MZL: a response-adapted trial
Ryan Lynch • 8 Dec 2023
3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals